From 20 October till 24 October 2023: HIGHLIGHTS FROM ESMO
Your direct line with Madrid
The European Society of Medical Oncology (ESMO) 2023 brings together leading experts in the different fields of cancer from around the world. And this year they gather together in Madrid, Spain. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the educational support of:
Presidential highlights
The ALINA trial was presented in the Presidential Session at ESMO 2023 by Prof Ben Solomon, focusing on adjuvant treatment options for patients with completely resected, ALK-translocated NSCLC. The main
The ESMO 2023 conference featured exciting data on lung cancer, including insights from the CheckMate 77T trial. The study was presented by Prof Tina Cascone, from the Department of Thoracic,
Prof Herbert Loong, representing the Chinese University of Hong Kong, presented a late-breaking abstract at ESMO 2023, the LIBRETTO 431 trial. This trial investigates the use of selpercatinib, a selective
At ESMO 2023, the results of the Papillon study, a phase 3 trial comparing amivantamab plus chemotherapy to chemotherapy alone in first-line treatment for EGFR exon 20 insertion-mutated non-transcendent (Ex20ins)
Until now, a single TKI has been the standard treatment in patients with EGFR-mutated, advanced NSCLC, but the goal of the MARIPOSA study was to do better with combination therapy.
Prof emeritus Johan Vansteenkiste discusses the outcomes of the MARIPOSA2 trial with prof Cho, medical oncologist at the Yonsei University Medical Center in Seoul, Korea.
MARIPOSA 2 is a global
Daily highlights in lung cancer
Dr Mariana Brandao, a medical oncologist at the Clinic of Thoracic Oncology at the Institute Jules Bordet in Brussels, provided insights into various mini-oral presentations focusing on non-metastatic NSCLC.
In the
The FLAURA2 trial, where initial data unveiled at the World Lung Conference showed that integrating chemotherapy into the standard care for EGFR-mutated patients significantly enhanced progression-free survival (PFS) by approximately
Professor Els Wauters, a respiratory oncologist at the University Hospital Leuven, discusses the proffered paper sessions of ESMO2023 in Madrid.
In the phase 3 SAPPHIRE trial, researchers investigated the impact
In the field of non-metastatic non-small cell lung cancer (NSCLC), Professor Lore Decoster, a medical oncologist at UZ Brussels, made a selection of abstracts presented during the proffered session on
In-depth stories about lung cancer
During ESMO 2023 MediMIx had the honour to organise a discussion on immunotherapy in NSCLC in difficult-to-treat populations with Prof Dirk De Ruysscher (UMC Maastricht) and Dr Lizza Hendriks
At ESMO 2023, exciting data on lung cancer were presented, including insights from the PACIFIC-06 study. The study was presented by Prof Marina Garassino, from the University of Chicago.
In
Prof Lore Decoster, a medical oncologist at UZ-Brussels, presented an analysis of the FINN study, a real-world prospective investigation into the combination of ipilimumab and nivolumab, often referred to as
Prof Martin Reck from the Lung Clinic Grosshansdorf presented game-changing insights. AEGEAN is the latest addition to perioperative chemoimmunotherapy trials for resectable NSCLC, akin to KEYNOTE 671, exploring the role
The KRYSTAL-7 study, presented at the ESMO Congress 2023, holds substantial promise for advancing the treatment of advanced NSCLC. This phase 2 trial focused on assessing a combination treatment involving
In this conversation at the ESMO Congress 2023 in Madrid, Mariana Brandão, a medical oncologist at the Jules Bordet Institute, and Lore Decoster, medical oncologist at the University Hospital Brussels,
Prof Nicolas Girard, Director of Medical Oncology at Institut Curie in Paris, presented an overview of the CheckMate 816 trial’s findings during the ESMO 2023 meeting. This randomised study focused
This symposium held during ESMO 2023 in Madrid centered on addressing the complex management of stage III NSCLC. MediMix gathered 3 experts to discuss various treatment strategies, including both surgical
Lung cancer poster selection
Dr Tamta Makharadze, medical oncologist at LTD High Technology Hospital Medical Center at Tbilisi, Georgia presented an exploratory subgroup analysis in patients with squamous NSCLC who were treated with cemiplimab
Dr Ana Baramidze, clinical researcher at the Todua Clinic in Tbilisi, Georgia described the outcomes of the EMPOWER-Lung 3 study, evaluating cemiplimab + chemotherapy in NSCLC patients with PD-L1 expression ≥1%.
Dr Mariana Brandão, medical oncologist at Jules Bordet Institut Brussels, summarizes the poster she presented.
Preliminary efficacy and safety of rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in
With the educational support of: